Phenoxodiol in Treating Patients With Refractory Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed solid tumor
• * Refractory to standard therapy OR
• * No standard therapy exists
• No breast cancer
• No active CNS metastases
• * Known CNS metastases must be previously treated with radiotherapy or surgery and stable for at least 4 weeks prior to study
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 60-100%
• Life expectancy:
• At least 3 months
• Hematopoietic:
• Platelet count greater than 100,000/mm\^3
• WBC greater than 3,000/mm\^3
• Neutrophil count greater than 1,500/mm\^3
• Hemoglobin greater than 10 g/dL (9 g/dL for women)
• Hepatic:
• Bilirubin less than 1.2 mg/dL
• Transaminases no greater than 3 times upper limit of normal
• Renal:
• Creatinine no greater than 1.4 mg/dL
• Other:
• No active infection
• No contraindication to the insertion of a vascular access device
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No concurrent systemic anticancer immunotherapy
• Chemotherapy:
• No concurrent systemic anticancer chemotherapy
• Endocrine therapy:
• No concurrent systemic anticancer hormonal therapy except luteinizing hormone-releasing hormone agonists or antagonists
• Radiotherapy:
• See Disease Characteristics
• Concurrent localized radiotherapy for control of local disease complications allowed
• Surgery:
• See Disease Characteristics
• Other:
• Recovered from prior antineoplastic therapy
• At least 4 weeks since prior investigational agents
• No other concurrent investigational drugs